China, Sept. 1 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Lorlatinib plus Sacituzumab Tirumotecan with Peripheral ctDNA Guidance as First‑Line Therapy for ALK Fusion‑Positive NSCLC'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600131220
Registration Time: 2026/08/31
Type: Interventional study
Primary Sponsor: Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=336452
Published by HT Digital Content Services with permission from Health Daily Digest....